Anti - Human IgG | MyBioSource MBS684242 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

Anti - Human IgG

catalog :

MBS684242

quantity :

1 mL (Prediluted)

price :

175 USD

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

clone name :

[E20-V]

application :

immunohistochemistry, immunohistochemistry - paraffin section

more info or order :

MyBioSource product webpage

image

image 1 :

product information

catalog number :

MBS684242

products type :

Antibody

products full name :

Anti - Human IgG

products short name :

[Human IgG]

other names :

[Ig gamma-1 chain C region; Ig gamma-1 chain C region; immunoglobulin heavy constant gamma 1 (G1m marker)]

other gene names :

[IGHG1; IGHG1]

uniprot entry name :

IGHG1_HUMAN

clonality :

polyclonal

clone :

[E20-V]

host :

rabbit

specificity :

Human

storage stability :

Store at +4°C.

tested application :

Immunohistochemistry (IHC) - Paraffin

app notes :

Dilution: 1:100-1:300. IHC-P Protocol - Instruction Manual: . 1. Deparaffinize the section in 3 changes of xylene, 10 minutes each. 2. Wash the section in 96%, 80% and 70% ethyl alcohol for 10 minutes each. 3. Rinse in distilled water, 2 x 5 minutes. 4. Block the endogenous peroxidase by incubating the tissue in 3% hydrogen peroxide (H 2 O 2 ) for 10 minutes. 5. Wash in distilled water, 2 x 5 minutes. 6. For antigen retrieval: Immerse the slide in Tris-EDTA buffer, pH 9.0 and incubate at 95-97ºC in water bath for 25 minutes. 7. Remove the staining to room temperature and let the slide to cool (in Tris-EDTA buffer, pH 9.0) for 15 minutes. 8. Rinse in distilled water, 2 x 5 minutes. 9. Wash in PBS (phosphate buffer saline, pH 7.0-7.5) supplemented with 0.05% of Tween-20 (buffer A), 2 x 5 minutes. 10. CONCENTRATED: . Incubate the section with primary antibody at the dilution 1:100 - 1:300 for 1 hour in the closed wet chamber. READY TO USE (RTU): Incubate the section with primary antibody (ready to use) for 1 hour in a closed wet chamber. 11. Wash 3 x 5 minutes with buffer A. 12. Apply the secondary antibody (the protocol depends on the supplier), and proceed to standard immunohistochemistry protocol (HRP - Peroxide - DAB). 13. Wash 3 x 5 minutes with buffer A. 14. Apply the chromogen (DAB), 1 - 3 minutes. 15. Wash in water, 2 x 5 minutes. 16. Stain in hematoxylin for 5 minutes. 17. Wash in distilled water, 3 x 2 minutes. 18. Mount the slide for observation. * Tris-EDTA Buffer (10mM Tris Base, 1mM EDTA solution, 0.05% Tween-20, pH 9.0): . Tris ----------- 1.21 g; EDTA ---------- 0.37 g; Distilled water ------------ 1000 ml . Mix to dissolve in 700 ml of distilled water. Adjust pH to 9.0 with 1M HCl and then add 0.5 ml of Tween-20 and mix well. Adjust the final volume to 1 liter with distilled water. Store this solution at room temperature for 3 months or at +4ºC for longer storage. Ventana Protocol - Instruction Manual: . SHORT APPLICATION PROTOCOL FOR VENTANA BENCHMARK SLIDE STAINING SYSTEM . 1. Drying (Enter). 2. Heating glass (72°C), incubation 4 min. Drying. 3. Deparafinization (Enter). 4. Heating (72°C) with the medium temperatures. Deparafinization. 5. Cell conditioning (Enter). 6. ULTRA Conditioner #1 (Enter). 7. Heating glass (95°C), incubation 8 min (Cell conditioner #1). 8. ULTRA CC1 solution application – 20 min (Enter). 9. Titration (Enter). 10. Hand apply – primary antibody. Incubation 24 min. 11. UltraWash (Enter). 12. Nuclear stain (Enter). 13. Hematoxylin application – one drop (nuclear stain), cover and incubate 8 min. 14. After nuclear stain (Enter). 15. Bluing reagent application, one drop. After nuclear stain, cover and incubate 4 min.

image1 heading :

Immunohistochemistry (IHC)

other info1 :

Buffer: 20 mM Tris-HCl, pH 8.0. Stabilizer: 20 mg/ml BSA. Preservative: 0.05% NaN 3 . Immunogen: Peptide derived from internal domain of human IgG-1 chain C region. Antibody recognizes the epitope between Val167 - Val185. Cellular Localizaton: Secreted. Positive Control: Human Tonsil Tissue. Precautions: 1. We strongly recommend to use a Primary Antibody Diluent, eventually alternative diluent (containing protease free BSA at the concentrations > 1mg/ml) for dilution of concentrated antibodies, otherwise the warranty might be voided. 2. Centrifuge the vial before use. 3. Intended for professional In Vitro Diagnostic use in laboratories. 4. Do not use after expiration date stamped on vial label. 5. Avoid contamination of the reagent. 6. Any discrepancies in the recommended procedures stated in the working protocol may affect the final results. 7. The reagent contains sodium azide (NaN 3 ) which is highly toxic in higher concentrations. The concentration in the reagent (0.05%) is not considered as hazardous. 8. Disposal of waste material must be conducted in accordance with local regulations. 9. Wear appropriate Personal Protective Equipment to avoid contact with eyes and skin.

ncbi gi num :

121039

ncbi acc num :

P01857.1

uniprot acc num :

P01857

ncbi pathways :

Classical Antibody-mediated Complement Activation Pathway (106409); Complement Cascade Pathway (106405); Creation Of C4 And C2 Activators Pathway (106407); FCGR Activation Pathway (771578); Fcgamma Receptor (FCGR) Dependent Phagocytosis Pathway (771577); IL4-mediated Signaling Events Pathway (137933); Immune System Pathway (106386); Initial Triggering Of Complement Pathway (106406); Innate Immune System Pathway (106387); Regulation Of Actin Dynamics For Phagocytic Cup Formation Pathway (771579)

uniprot summary :

Subcellular location: Secreted. Involvement in disease: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.Note: The disease is caused by mutations affecting the gene represented in this entry. A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4. Miscellaneous: Nie has the G1M17 allotypic marker, 97-K, and the G1M1 markers, 239-D and 241-L. KOL and EU sequences have the G1M3 marker and the G1M (non-1) markers. Sequence caution: The sequence AAC82527.1 differs from that shown. Reason: Erroneous initiation.

size1 :

1 mL (Prediluted)

price1 :

175 USD

size2 :

0.04 mL (Concentrate)

price2 :

185

size3 :

0.1 mL (Concentrate)

price3 :

345

size4 :

7 mL (Prediluted)

price4 :

365

size5 :

0.2 mL (Concentrate)

price5 :

465

size6 :

15 mL (Prediluted)

price6 :

540

size7 :

0.5 mL (Concentrate)

price7 :

585

size8 :

1 mL (Concentrate)

price8 :

895

more info or order :

MyBioSource product webpage